Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Wraps Up NovaScreen Acquisition

NEW YORK, Oct. 4 (GenomeWeb News) - Caliper Life Sciences has completed its acquisition of NovaScreen Biosciences for up to $30 million, the companies said today.


Caliper can now set its sights on the outsourced assay-development and -screening markets, "especially" the secondary screening and profiling -services market, the company said in a statement. The acquisition could also enable Caliper to play a greater role in the kinase-screening market.


As GenomeWeb News reported last month, Caliper Life Sciences planned to acquire NovaScreen for $22 million, subject to certain financial parameters, and up to an additional $8 million, depending on revenue milestones over the next 30 months. Eighty percent of the payments will be made in Caliper common stock and 20 percent in cash.


Caliper said it expects NovaScreen to contribute approximately $2 million to its revenues.


Hanover, Md.-based NovaScreen focuses on in vitro screening assays and in silico predictive screening tools, with particular expertise in receptor pharmacology.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.